Scientists representing the Moscow state University. M. V. Lomonosov Moscow state University, together with experts from the UK and Germany have created a prototype of new drugs against autoimmune diseases. The proposed method involves scientists disable dangerous functions in one of the proteins of the organism while maintaining its useful functions
In the centre of the investigation was a protein called TNF. It performs many tasks, including to protect people from tuberculosis and other diseases. However, it can also play a negative role in the emergence of such autoimmune diseases as rheumatoid arthritis, psoriasis and Crohn’s disease. Thus, in some situations, the hazards may be how to suppress the activity of TNF, and the rejection of this suppression.
In search of a solution to this problem the specialists of Moscow state University suggested that artificial antibodies, called bespecifically, can help to selectively suppress TNF in macrophages, which in autoimmune diseases produce, mainly, “bad” TNF, but it does not interfere with the “good” of TNF. Further research showed that this conjecture was correct. A new type bespecifically antibodies, developed for the purposes of this verification, was named MYSTI (Myeloid-Specific TNF Inhibitor).
The experiments to test the effectiveness and safety of a new agent against autoimmune diseases, was conducted on genetically modified mice with “human” version of a TNF protein (such mice are called “humanized”). After treatment bespecifically antibodies secreted by macrophages TNF were not allocated but were associated with their surface. In another experiment in mice caused septic shock, mediator as “bad” TNF from macrophages. While MYSTI was protected mice from lethal toxicity, and the control antibody does not.